Company Watch

Glenmark receives MHRA approval for Baddi plant

Our News Bureau - Mumbai

Glenmark Pharmaceuticals has received approval from MHRA of UK for its state of the art semi-solids (ointments & creams) manufacturing plant at Baddi, Himachal Pradesh. This is the third of Glenmark's manufacturing plants to have been approved for GMP by the UK regulatory agency—MHRA. This will enable Glenmark's foray into the supply of creams and ointments in Europe soon. The Baddi plant had already received GMP approval from TPD, Canada, and is well on course to receiving USFDA approval in the near future, which would enable Glenmark to enter the niche segment of semi-solid dosages in most of the regulated markets of the world.

"The approval from MHRA, UK will provide further impetus to our current expansion efforts in the European region. Our plant at Baddi has been built to the highest international standards and has been producing batches for filing in Europe and the US. Glenmark has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets and we look forward to the US FDA approval for Baddi as the next milestone," said Glenn Saldanha, Chief Executive Officer and Managing Director, Glenmark. Glenmark's facility at Baddi is fully commissioned with more than Rs 2300 million worth of production coming from this facility. Baddi presently supplies Glenmark's Indian requirements and has produced batches for filing in the US and Europe. The company hopes that the Baddi facility will break-even in its first two years of operation.